drugset / Trial / NCT01038037
First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to determine whether the addition of panitumumab to standard chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the treatment outcome. Patients are selected based on triple mutational status.
Timeline
- Start
- 2010-01
- Primary completion
- 2013-06
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | 9 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 5 mg | Intravenous |
| Background | Vinorelbine | Small molecule | 30 mg/m2 | Intravenous |
| Background | Vinorelbine | Small molecule | 60 mg/m2 | Intravenous |